© BusinessWire
05.01.2026
NEOG
LISTED
NASDAQ
Neogen® Announces Two Senior Leadership Appointments
News Preview
Neogen Corporation (NASDAQ: NEOG) today announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026.
As Senior Vice President and General Manager for Neogen’s Food Safety...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
MTVA
LISTED
NASDAQ
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
News Preview
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54Strong Glycemic Response with a 12.3 mg/dL Fasted Glucose Reduction by Day 54Robust Weight Loss with 9.1% Reduction (21.2 lbs) by Day 54CAMBRIDGE, Mass., Jan. 5, 2026 /PR...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
COSM
LISTED
NASDAQ
Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
News Preview
Cosmos Health signs a manufacturing agreement with Lybitec for PathMuscle, targeting expected production volumes of over 1.2 million units in five years....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
05.01.2026
CHRS
LISTED
NASDAQ
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
News Preview
-Coherus Oncology formally introduces non-proprietary name: tagmokitug-...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
05.01.2026
WGS
LISTED
NASDAQ
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its position as the global leader in rare disease genomics. In 2025, GeneDx published 79 peer-reviewed studies bringing its total to over 1,100 peer-reviewe...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
ESLA
LISTED
NASDAQ
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
News Preview
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
SRPT
LISTED
NASDAQ
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 12, 2026 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A sessi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
PCSA
LISTED
NASDAQ
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
News Preview
Interim safety and efficacy data to be reported in Q1...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
AVTR
LISTED
NYSE
Avantor® to Participate in 44th Annual J.P. Morgan Healthcare Conference
News Preview
RADNOR, Pa., Jan. 5, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Emmanuel Ligner, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
GDRX
LISTED
NASDAQ
GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy® Pill
News Preview
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per month at more than 70,000 pharmacies nationwide via GoodRx. For consumers looking to easily evaluate their options for both treatment and access to...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
SNDA
LISTED
NYSE
Sonida Senior Living Announces $900 Million of Permanent Debt Financing Commitments in Connection with CNL Healthcare Properties, Inc. Strategic Merger
News Preview
Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in senior living communities, announced today that in connection with the previously announced definitive merger agreement (the “Merger Agreement”) with CNL Healthcare Properties, Inc. (“CHP”), Sonida has obtained committed permanent debt fi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
05.01.2026
ODYS
LISTED
NASDAQ
Odysight.ai Inc. Announces Website Posting of CEO Letter to Shareholders
News Preview
Englewood, New Jersey, US, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ:ODYS), a leader in AI-powered visual sensing and Predictive Maintenance (PdM) technologies, today announced that it had posted a CEO letter to shareholders on the Company’s investor relations website at https://www.odysight.ai/. The CEO letter to shareholders is...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
BNBX
LISTED
NASDAQ
BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order
News Preview
BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accel...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
ABBV
LISTED
EURONEXT
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on December 31, 2025, Edgewise granted inducement stock options to pur...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
DRTS
LISTED
NASDAQ
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
News Preview
- Initial module submission marks an important milestone in the pre-market approval process - ...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
PRFX
LISTED
NASDAQ
PainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market
News Preview
New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnar...
Themefolio
Profiler
Peergroup
© Newsfile
05.01.2026
PHRX
LISTED
CSE
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
News Preview
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 3...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
LCTX
LISTED
TLV
Lineage Cell Therapeutics Issues Letter to Stockholders
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company’s achievements throughout 2025 and its corporate outlook for 2026.
To Our Sharehol...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
GEHC
LISTED
NASDAQ
GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026
News Preview
GE HealthCare (Nasdaq: GEHC) will announce its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 4, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
SRRK
LISTED
NASDAQ
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that ma...
Themefolio
Profiler
Peergroup
© Newsfile
05.01.2026
OSTX
LISTED
XASE
OS Therapies Provides First Half 2026 Corporate Outlook
News Preview
Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 program in the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (Metastatic Osteosarcoma Program) under Accelerated Approval ProgramBiomarker data from Phase 2b Metastatic Osteosarcoma Progr...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
DCGO
LISTED
NASDAQ
DocGo Announces Upcoming Participation at 28th Annual Needham Growth Conference
News Preview
DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled mobile health and medical transportation services, announced today that Norm Rosenberg, Chief Financial Officer, will hold a fireside chat at the 28th Annual Needham Growth Conference on Wednesday, January 14th at 1:30 PM Eastern Time, and will be participating in 1x1 me...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
ASND
LISTED
NASDAQ
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
XENE
LISTED
NASDAQ
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
WVE
LISTED
NASDAQ
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morg...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
BDRX
LISTED
NASDAQ
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
News Preview
January 05, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
NGNE
LISTED
NASDAQ
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference.
Format: Management will present a company overview and participate...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
INCY
LISTED
NASDAQ
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
News Preview
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednis...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
USPH
LISTED
NYSE
U.S. Physical Therapy Announces the Acquisition of an Eight-Clinic Physical Therapy Management Services Company
News Preview
U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced the acquisition of a physical therapy management services company, which exclusively manages a physical therapy practice with eight clinic locati...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
AGL
LISTED
NYSE
agilon health, inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – AGL
News Preview
The DJS Law Group reminds investors of a class action lawsuit against agilon health, inc. (“Agilon” or “the Company”) (NYSE: AGL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of AGL during the clas...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
ZLAB
LISTED
NASDAQ
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026, at 3:00 p.m. PST / 6:00 p.m. EST.
A live webcast of the presentation will be available on the Investor Relations page of Zai Lab’s we...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapie...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
LFMD
LISTED
NASDAQ
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
News Preview
Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
NEO
LISTED
NASDAQ
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics’ management is scheduled to present and participate in a Q&A session on Tuesday, January 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
CPRX
LISTED
NASDAQ
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
News Preview
Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
NCEL
LISTED
NASDAQ
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
News Preview
ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big p...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
HALO
LISTED
NASDAQ
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
News Preview
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimabSAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
RDHL
LISTED
NASDAQ
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
News Preview
RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects--Largey de-risked, RHB-102 development is supported by published posit...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
KRYS
LISTED
NASDAQ
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
ESPR
LISTED
NASDAQ
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
News Preview
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
OSUR
LISTED
NASDAQ
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
News Preview
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
SYK
LISTED
NYSE
Stryker to announce financial results for its fourth quarter and full year 2025
News Preview
Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary fi...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
KRMD
LISTED
NASDAQ
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursu...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
BEAT
LISTED
NASDAQ
HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference
News Preview
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA.
HeartBeam Chief Executive Officer, Rob...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
NTRA
LISTED
NASDAQ
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s expanded 21-gene Fetal Focus single gene non-invasive prenatal test (sgNIPT), supported by new findings from the blinded prospective EXPAND clinical trial. Results from this analysis demonstrate the test’s ability to detect...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcar...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
UTHR
LISTED
NASDAQ
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will present a company overview and update on Monday, January 12, 2026, from 1:30 to 2:10 p.m. PST, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation can be accessed via a live...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
TAK
LISTED
NYSE
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
News Preview
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously adminis...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
BDX
LISTED
NYSE
BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial
News Preview
FRANKLIN LAKES, N.J., Jan. 5, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product's expanded indication for prop...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2026
MRK
LISTED
NYSE
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Monday,...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-1...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
KURA
LISTED
NASDAQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on January 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) g...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
BBIO
LISTED
NASDAQ
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
News Preview
PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
PTHS
LISTED
XASE
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
News Preview
DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 millio...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
News Preview
The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development str...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
ALT
LISTED
NASDAQ
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
News Preview
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.01.2026
ZBIO
LISTED
NASDAQ
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
News Preview
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -...
Themefolio
Profiler
Peergroup
© PR Newswire
05.01.2026
IDYA
LISTED
NASDAQ
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
